Novo Nordisk Sues Makers of Wegovy and Ozempic Dupes
XTalks
JULY 10, 2023
With the remarkable success of its semaglutide products Wegovy and Ozempic for weight loss and type 2 diabetes, respectively (the latter also for weight loss through off-label prescribing), Novo Nordisk is cracking down on pharmacies making compounded versions of the glucagon-like peptide-1 (GLP-1) receptor agonist drugs.
Let's personalize your content